Using the publicly available microarray datasets from PrognoScan (http://www.abren.net/PrognoScan/), we found that higher expression of PRDM5 predicted significantly lower OS in AML patients (Figure 1C). Here, PRDM5 is linked to acute myeloid leukemia.